Myoderm Breaks Ground On New U.S. Headquarters

Norristown, PA – 07/09/20



Norristown, PA, July 9, 2020 – Myoderm, a leading global clinical trial supply company, broke ground for their new global headquarters and US operational facility on a 14-acre site in Horsham, Pa.

“This new facility is the next stage of our evolving support for clinical drug development,” James Lovett, Myoderm’s Chief Executive Officer, said at the groundbreaking on July 9. “It will greatly expand our existing drug storage and distribution capability, especially for cold-chain biologics, and will support our rapidly growing newer services in packaging and labeling, clinical trial equipment and supplies, and CTRx prescription cards for use in clinical trials.”

The 65,000-square-foot facility will include 20,000-sq.-ft. of office space and a 45,000-sq.-ft. warehouse and distribution center with staging, shipping and receiving areas; rack storage in ambient temperatures and 2–8-degree Celsius cold box; -20-degree C and -80-degree C freezer storage; and secondary labeling rooms, all designed to current good manufacturing practices (cGMP) guidelines.


Myoderm Groundbreaking


The company’s roots date back to 1935, when Morris Cohen purchased an independent pharmacy in Norristown. Myoderm has been under Cohen family ownership for three generations and maintains headquarters in North America and the United Kingdom.

“Our future has never been brighter, and it’s because of you that it is. The best is yet to come,” Michael Cohen, Myoderm Executive Chairman and grandson of the company founder, told employees in the audience at the groundbreaking ceremony.

Addressing the audience, which also included Horsham Township officials and business leaders, Lovett expressed appreciation for the support of Horsham Township leadership and other stakeholders who worked with Myoderm to enable the groundbreaking to occur on schedule despite the challenges of the COVID-19 pandemic.

Myoderm Groundbreaking


“As we all sit with masks on, socially distanced because of the COVID-19 pandemic, clinical trials have never been more in the news, clinical trials have never been more important,” he said. “Supporting clinical trials is everything we do at Myoderm.”


Myonex News